Metabolic disease is our center of gravity.
It is one of the most consequential frontiers in biotech — and one where deep biology, fast-moving clinical evidence, and competitive dynamics constantly overlap. Our work spans diabetes and obesity, incretin and islet biology, MASH/MASLD, chronic kidney disease and cardiometabolic organ protection, biomarkers and translational endpoints, and the evidence strategy that turns all of it into defensible positioning.
Where the science and the strategy meet
Metabolic disease is a fast-moving, scientifically dense field. The work below stays grounded in mechanism and evidence — translating biology into clear, defensible strategic direction rather than hype.
GLP-1, GIP, glucagon, and polyagonist strategy
Incretin and multi-receptor agonist positioning, mechanism differentiation, and competitive context across the obesity and type 2 diabetes pipeline.
Islet biology and beta-cell function
Mechanistic framing of beta-cell health, insulin secretion, and islet-directed approaches relevant to disease modification.
Obesity and type 2 diabetes platforms
Asset and platform evaluation across crowded metabolic markets, with attention to durability, tolerability, and mechanism.
Translational biomarkers and mechanism framing
Connecting preclinical mechanism to clinical readouts and decision-relevant endpoints that hold up under diligence.
Academic spinout and early asset positioning
Translating discoveries into credible, investable development narratives with a clear scientific rationale.
Competitive differentiation in crowded metabolic markets
Identifying defensible scientific and strategic whitespace where a program can credibly stand apart.
Cardiometabolic organ protection
Framing the multi-organ reach of metabolic disease — chronic kidney disease, MASH, heart failure, and vascular risk — and what it means for endpoint and indication strategy.
This focus complements, and never replaces, a sponsor's own clinical, regulatory, and medical judgment. Engagements remain scientific and strategic advisory.
Evidence-graded, not hype-driven
Metabolic science moves quickly, and not every claim is equal. Across diabetes, obesity, islet and beta-cell biology, MASH, kidney, and cardiometabolic disease, we hold three things apart — what is approved, what is strong but still investigational trial evidence, and what is emerging — and label every claim by how strong the underlying evidence actually is. That discipline is what keeps strategy defensible under diligence.
GLP-1 and Incretin Therapeutics
A worked example of Valdez BioStrategy's evidence-graded approach to fast-moving metabolic science — separating approved indications from trial evidence and emerging frontiers, and reading mechanism carefully against outcome.
Read the reportOne example of our work — not the whole practice. Browse all Strategy Reports.
A metabolic disease question to pressure-test?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? contact@valdezbiostrategy.com